Literature DB >> 19277508

HIF-1alpha-dependent gene expression program during the nucleic acid-triggered antiviral innate immune responses.

Sun Woo Hong1, Jae Wook Yoo, Hye Suk Kang, Soyoun Kim, Dong-Ki Lee.   

Abstract

Recent studies suggest a novel role of HIF-1alpha under non-hypoxic conditions, including antibacterial and antiviral innate immune responses. However, the identity of the pathogen-associated molecular pattern which triggers HIF-1alpha activation during the antiviral response remains to be identified. Here, we demonstrate that cellular administration of double-stranded nucleic acids, the molecular mimics of viral genomes, results in the induction of HIF-1alpha protein level as well as the increase in HIF-1alpha target gene expression. Whole-genome DNA microarray analysis revealed that double-stranded nucleic acid treatment triggers induction of a number of hypoxia-inducible genes, and induction of these genes are compromised upon siRNA-mediated HIF-1alpha knock-down. Interestingly, HIF-1alpha knock-down also resulted in down-regulation of a number of genes involved in antiviral innate immune responses. Our study demonstrates that HIF-1alpha activation upon nucleic acid-triggered antiviral innate immune responses plays an important role in regulation of genes involved in not only hypoxic response, but also immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277508     DOI: 10.1007/s10059-009-0030-2

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  8 in total

1.  Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2.

Authors:  Barbara Testoni; Christine Völlenkle; Francesca Guerrieri; Sabine Gerbal-Chaloin; Giovanni Blandino; Massimo Levrero
Journal:  J Biol Chem       Date:  2011-04-15       Impact factor: 5.157

2.  Selection and optimization of asymmetric siRNA targeting the human c-MET gene.

Authors:  Seul-gi Jo; Sun Woo Hong; Jae Wook Yoo; Chang Han Lee; Sera Kim; Soyoun Kim; Dong-ki Lee
Journal:  Mol Cells       Date:  2011-11-03       Impact factor: 5.034

3.  Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha.

Authors:  Alessio Paone; Roberta Galli; Chiara Gabellini; Dmitriy Lukashev; Donatella Starace; Agnes Gorlach; Paola De Cesaris; Elio Ziparo; Donatella Del Bufalo; Michail V Sitkovsky; Antonio Filippini; Anna Riccioli
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

4.  C. elegans SWAN-1 Binds to EGL-9 and regulates HIF-1-mediated resistance to the bacterial pathogen Pseudomonas aeruginosa PAO1.

Authors:  Zhiyong Shao; Yi Zhang; Qi Ye; Jenifer Neeta Saldanha; Jo Anne Powell-Coffman
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

Review 5.  Hypoxia-Inducible Factor (HIF) as a Pharmacological Target for Prevention and Treatment of Infectious Diseases.

Authors:  Tamara Bhandari; Victor Nizet
Journal:  Infect Dis Ther       Date:  2014-06-24

6.  Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.

Authors:  Lin Kong; Jing Gao; Jiyi Hu; Rong Lu; Jing Yang; Xianxin Qiu; Weixu Hu; Jiade J Lu
Journal:  Cancer Commun (Lond)       Date:  2019-02-20

7.  The hypoxia-inducible transcription factor ZNF395 is controlled by IĸB kinase-signaling and activates genes involved in the innate immune response and cancer.

Authors:  Darko Jordanovski; Christine Herwartz; Anna Pawlowski; Stefanie Taute; Peter Frommolt; Gertrud Steger
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

8.  SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients.

Authors:  Juan Bizzotto; Pablo Sanchis; Mercedes Abbate; Sofía Lage-Vickers; Rosario Lavignolle; Ayelén Toro; Santiago Olszevicki; Agustina Sabater; Florencia Cascardo; Elba Vazquez; Javier Cotignola; Geraldine Gueron
Journal:  iScience       Date:  2020-09-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.